|
| Thursday, 22 December 2016, 15:20 HKT/SGT | |
| |  | |
Source: Eisai | |
|
|
|
|
| Accelerating the Discovery of Novel Drug Targets That May Lead to Development of New Therapeutics for Dementia |
TOKYO, Dec 22, 2016 - (JCN Newswire) - Eisai Co., Ltd. and Keio University announced today that they have entered into a new joint research agreement for the discovery and development of new drugs targeting dementia. For this collaborative research, a research lab will be established, and researchers from Eisai and Keio University will work together to identify and validate novel drug targets and biomarkers that could potentially lead to the development of new therapeutics and preventive medicines for dementia.
Under this joint research agreement, Eisai and Keio University will establish the Eisai-Keio Innovation Lab for Dementia (tentative name) as a base for industry-academia collaboration within Keio University's Shinanomachi campus (Shinjuku ward, Tokyo) that will hopefully spur new innovation in the treatment of dementia. The lab will be an integrated research site for clinical medicine and basic medicine, and will be staffed by experienced researchers from both organizations.
Beginning with the Center for Supercentenarian Medical Research, Keio University possesses strengths in researching medicine and medical care through unifying basic and clinical science. Keio University has also published extensively about its world-class research into human iPS cells.
Eisai, which utilizes a drug development technology that produces small molecule compounds, mid-size compounds derived from natural products and antibodies, has been active in the field of developing new dementia drugs for over 30 years. Together with information provision activities relating to Aricept (donepezil hydrochloride), Eisai has accumulated a vast amount of experience and knowledge in the field of dementia.
At the Innovation Lab, Eisai and Keio University will bring together their respective strengths and, using new approaches that focus on genetic backgrounds, environmental factors, and protective mechanisms based upon healthy longevity, aim to speed up research of new drug targets and biomarkers for dementia as well as increase the probability of success in new drug discovery. The Innovation Lab will perform three functions: Clinical Omics Analysis, utilizing the latest mass spectroscopy technology; Data Science, utilizing artificial intelligence to determine new drug targets; and Biological Validation, which makes use of human iPS cell technology to advance the study of drug target biology. These research functions, along with the central concept of "Bidirectional Translation Cycle", which repeatedly generates new hypotheses based on human biology and validates them with models, will lead to accurate understanding of the disease, through which useful biomarkers and drug targets can be discovered and applied towards new therapeutics.
"Dementia is one of the major social and medical issues in an aging society, and Eisai's mission is to contribute to overcoming this issue" said Teiji Kimura, Chief Discovery Officer of the Eisai Neurology Business Group. "Eisai's strengths are its computational technology, drug discovery and biomarker research capabilities in the field of neurology. Through this Innovation Lab, we can collaborate with Keio University which has world-class iPS cell technology and expertise in basic medical science and clinical science, leading to new innovations, and allowing us to get new treatments to patients as soon as possible."
Hideyuki Okano, Dean of Keio University School of Medicine remarked "The establishment of this innovation lab allows us to combine Eisai's accumulated experience of dementia drug discovery such as Aricept with Keio University's supercentenarian medical research and dementia research, mutually boosting our competitive power, and culminating in an amazing opportunity to develop practical applications."
About Keio University
Keio University promotes comprehensive research on topics directly related to fields of life science and medical care through close cooperation among various faculties, graduate schools, and advanced research centers, such as the Faculty of Medicine, Faculty of Nursing and Medical Care, Faculty of Pharmacy, Faculty of Science and Technology, and Faculty of Environment and Information Studies; as well as the Institute for Advanced Biosciences (IAB).
In particular, Keio University is noted as a center of research excellence in Japan in the fields of regenerative medicine using iPS and stem cells, as well as in immunology. In 2014, the Clinical and Translational Research Center was established in Keio University Hospital to coordinate all stages of the R&D process from translational research to clinical studies and clinical trials.
On March 25, 2016, Keio University Hospital was accredited as a Core Clinical Research Hospital under the Medical Care Act promoting high-quality clinical research and clinical trials necessary to develop the next generation of innovative medicines and medical devices in Japan; and for its role as a leading hospital conducting investigator-initiated clinical trials and clinical research at an international standard.
As the School of Medicine approaches its centennial anniversary in 2017, it is accelerating its efforts to further improve its capabilities as a world-leading comprehensive center for medical education, research, and care.
For more information about Keio University, please visit www.keio.ac.jp/en/
Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Topic: Press release summary
Source: Eisai
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| Eisai |
| Dec 23, 2024 16:22 HKT/SGT |
|
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases |
| Dec 11, 2024 13:45 HKT/SGT |
|
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia |
| Dec 5, 2024 10:22 HKT/SGT |
|
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico |
| Nov 28, 2024 15:26 HKT/SGT |
|
LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea |
| Nov 26, 2024 14:50 HKT/SGT |
|
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan |
| Nov 20, 2024 10:51 HKT/SGT |
|
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan |
| Nov 20, 2024 09:24 HKT/SGT |
|
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements |
| Nov 15, 2024 16:33 HKT/SGT |
|
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment) |
| Nov 15, 2024 13:31 HKT/SGT |
|
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease |
| Nov 5, 2024 10:35 HKT/SGT |
|
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem" |
| More news >> |
 |
|
|
|
